Mazyar Shadman, MD, discusses the potential utility of LOXO-305 in chronic lymphocytic leukemia.
Mazyar Shadman, MD, MPH
Advertisement
Mazyar Shadman, MD, MPH, is the Innovators Network Endowed Chair and an associate professor, in theClinical Research Division at Fred Hutchinson Cancer. He is also an associate professor in the Medical Oncology Division at University of Washington School of Medicine.
Articles by Mazyar Shadman, MD, MPH
Mazyar Shadman, MD, shares treatment considerations for patients with chronic lymphocytic leukemia.
Mazyar Shadman, MD, MPH, assistant member, Fred Hutchinson Cancer Research Center, discusses next steps for CAR T-cell therapy in diffuse large B-cell lymphoma.
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
4
Ixazomib-Containing Combinations Signal Potential for More PI-Based Regimens in R/R Multiple Myeloma
5